Gwenn Hansen Sells 4,356 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total value of $108,900.00. Following the sale, the insider directly owned 117,227 shares in the company, valued at approximately $2,930,675. The trade was a 3.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Stock Up 0.4%

NRIX stock opened at $25.22 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $25.49. The stock’s 50 day moving average is $21.11 and its two-hundred day moving average is $18.00. The company has a market capitalization of $2.62 billion, a PE ratio of -7.31 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The business had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Institutional Investors Weigh In On Nurix Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NRIX. General Atlantic L.P. acquired a new position in Nurix Therapeutics in the fourth quarter worth $92,899,000. Morgan Stanley raised its holdings in shares of Nurix Therapeutics by 115.9% during the fourth quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after purchasing an additional 2,620,323 shares during the period. Rubric Capital Management LP acquired a new stake in shares of Nurix Therapeutics during the fourth quarter worth $46,930,000. Braidwell LP bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $41,428,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Nurix Therapeutics by 195.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock worth $61,622,000 after buying an additional 2,149,268 shares during the last quarter.

Analysts Set New Price Targets

Several analysts recently issued reports on NRIX shares. Jefferies Financial Group upped their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Needham & Company LLC reissued a “buy” rating and set a $34.00 price objective on shares of Nurix Therapeutics in a report on Tuesday. Morgan Stanley boosted their target price on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Finally, UBS Group increased their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.00.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.